Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence

There are no seroprevalence terms in the subcorpus

    displaying 1 - 1 records in total 1
    records per page




    Effect of hydroxychloroquine on COVID-19 prevention in cancer MESHD patients undergoing treatment: A structured summary of a study protocol for a randomised controlled trial.

    Authors: Abolghasem Allahyari; Hossein Rahimi; Majid Khadem-Rezaiyan; Zahra Mozaheb; Mohsen Seddigh-Shamsi; Alireza Bary; Mostafa Kamandi; Sajad Ataei Azimi; Saeed Eslami HasanbAbadi; Alireza Noferesti; Somayeh Sadat Shariatmaghani; Houshang Rafatpanah; Shohreh Khatami; Afshin Jabbar Imani; Hassan Mortazi; Mohammad Moeini Nodeh

    doi:10.21203/rs.3.pex-969/v1 Date: 2020-06-05 Source: ResearchSquare

    This is a multi-center, two-arm, parallel-group, triple-blind, phase 2-3 randomised controlled trial. All patients over the age TRANS of 15 from 5 types of cancer MESHD, acute lymphoid MESHD and myeloid leukemias HP myeloid leukemias MESHD, non-Hodgkin's lymphoma MESHD lymphoma HP, breast and colon cancer MESHD colon cancer HP will enter the study. Patients are randomly assigned to two groups. During two months of treatment, the two groups are treated with either hydroxychloroquine or placebo. Patients will be monitored for COVID-19 symptoms. The primary end point of the study is to investigate the incidence of COVID-19 in patients.Randomisation will be performed using randomly permuted blocks. The allocation ratio in two groups is 1:1. Participants, caregivers, outcome assessor and the data analyst are blinded to group assignment.The calculated total sample size is 60 patients, with 30 patients in each group. The trial began on April 14, 2020 and recruitment is ongoing. Recruitment is anticipated to be completed by June 14, 2020. This trial has been registered on the Iranian Registry of Clinical Trials (IRCT) with the registration number of IRCT20200405046958N1.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.